Results 41 to 50 of about 54,698 (337)
68Ga‐nitroimidazole PET/CT imaging of hypoxia in tuberculosis: A case series
Journal of Medical Radiation Sciences, Volume 69, Issue 4, Page 518-524, December 2022., 2022 There is increasing application of PET/CT imaging in infectious diseases such as tuberculosis. Imaging potential stressors such as hypoxia, using a novel Ga‐68 labelled hypoxia seeking agent, has the potential to identify patients who may benefit from individualised treatment strategies.
Philippa L Bresser +3 more
wiley +1 more source
Development of new copper-64 labeled rhodamine: a potential PET myocardial perfusion imaging agent
EJNMMI Radiopharmacy and Chemistry, 2022 Background Myocardial perfusion imaging (MPI) is one of the most commonly performed investigations in nuclear medicine procedures. Due to the longer half-life of the emerging positron emitter copper-64 and its availability from low energy cyclotron ...
Norah AlHokbany +5 more
doaj +1 more source
Development Strategy for Innovation System of Radiopharmaceuticals in China
中国工程科学, 2022 Nuclear medicine plays an irreplaceable role in the diagnosis, therapy, and prognosis of various diseases. Radiopharmaceuticals are the cornerstone of nuclear medicine; their systematic development could accelerate the innovation and clinical application
Peng Shuming +5 more
doaj +1 more source
Journal of Medical Radiation Sciences, Volume 69, Issue 4, Page 415-418, December 2022., 2022 PET has experienced exponential growth over the last few decades in terms of innovative technologies and novel radiopharmaceuticals. This has fostered increasing collaboration between radiographers and nuclear medicine technologists. Abstract Positron emission tomography (PET) as an imaging modality has undergone considerable innovation over the past ...
Sally L. Ayesa, Andrew Murphy
wiley +1 more source
New results on proton-induced reactions on Vanadium for $^{47}$Sc production and the impact of level densities on theoretical cross sections [PDF]
, 2021 New data for the $^\mbox{nat}$V(p,x) reactions have been measured in the range 26-70 MeV, with production of the nuclides $^{47}$Sc, $^{43}$Sc, $^{44m}$Sc, $^{44g}$Sc, $^{46}$Sc, $^{48}$Sc, $^{42}$K, $^{43}$K, $^{48}$V, $^{48}$Cr, $^{49}$Cr, and $^{51}$Cr.
arxiv +1 more source
Applications of carbon dots on tumour theranostics
View, 2021 Carbon dots (CDs) have been extensively investigated as prime candidates for developing tumour theranostic platform due to their tunable fluorescence emission and excitation, good photostability, high water solubility and biocompatibility.
Hao Wu +6 more
doaj +1 more source
Insight into the Development of PET Radiopharmaceuticals for Oncology
Cancers, 2020 While the development of positron emission tomography (PET) radiopharmaceuticals closely follows that of traditional drug development, there are several key considerations in the chemical and radiochemical synthesis, preclinical assessment, and clinical ...
Joseph Lau +5 more
semanticscholar +1 more source
Coded Aperture and Compton Imaging for the Development of $^{225}$Ac-based Radiopharmaceuticals [PDF]
arXiv, 2022 Targeted alpha-particle therapy (TAT) has great promise as a cancer treatment. Arguably the most promising TAT radionuclide that has been proposed is $^{225}$Ac. The development of $^{225}$Ac-based radiopharmaceuticals has been hampered due to the lack of effective means to study the daughter redistribution of these agents in small animals at the ...
arxiv
Chemical Engineering Journal Advances, 2023 The entry of no-carrier-added (NCA) 177Lu in the arena of clinical nuclear medicine has revolutionized the practice of targeted radionuclide tumor therapy.
Sourav Patra +4 more
doaj
mAbs, 2023 Monoclonal antibody (mAb) production using non-human cells can introduce non-human glycan epitopes including terminal galactosyl-α1–3-galactose (α1–3-Gal) moieties. Cetuximab is a commercial mAb associated with causing anaphylaxis in some patients due to
Grayson Hatfield +5 more
doaj +1 more source